Shanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines

Stock News

2025/12/15

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. ("Shangyao Zhongxi"), recently received a drug registration certificate from the Philippine Food and Drug Administration for its hydroxychloroquine sulfate tablets, approving the drug for market launch.

Hydroxychloroquine sulfate tablets are primarily used to treat rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin conditions triggered or worsened by sunlight.

The approval of hydroxychloroquine sulfate tablets (200mg) by the Philippine FDA signifies that the company is now qualified to sell the drug in the Philippine market. This milestone is expected to positively impact Shanghai Pharmaceuticals' overseas expansion efforts while providing valuable experience in international market development.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1153257892"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153257892\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153257892?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 16:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153257892","market":"us","top_or_hot":-1,"title":"Shanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration certificate from the Philippine Food and Drug Administration for its hydroxychloroquine sulfate tablets, approving the drug for market launch.</p>\n<p>Hydroxychloroquine sulfate tablets are primarily used to treat rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin conditions triggered or worsened by sunlight.</p>\n<p>The approval of hydroxychloroquine sulfate tablets (200mg) by the Philippine FDA signifies that the company is now qualified to sell the drug in the Philippine market. This milestone is expected to positively impact Shanghai Pharmaceuticals' overseas expansion efforts while providing valuable experience in international market development.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-12-15 16:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration certificate from the Philippine Food and Drug Administration for its hydroxychloroquine sulfate tablets, approving the drug for market launch.</p>\n<p>Hydroxychloroquine sulfate tablets are primarily used to treat rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin conditions triggered or worsened by sunlight.</p>\n<p>The approval of hydroxychloroquine sulfate tablets (200mg) by the Philippine FDA signifies that the company is now qualified to sell the drug in the Philippine market. This milestone is expected to positively impact Shanghai Pharmaceuticals' overseas expansion efforts while providing valuable experience in international market development.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白馬股","start_time":0,"source_url":"","article_id":"1153257892","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153257892","pubTimestamp":1765786358,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0175":"白马股","BK0012":"证金概念","BK0196":"行业龙头","BK0187":"一线龙头","BK0184":"上海国资改革","BK0097":"医药电商","BK0028":"国家队","BK0099":"上海本地重组","BK0020":"浦东新区","BK1197":"保健护理产品经销商","02607":"上海医药","BK0183":"MSCI概念","BK0209":"零售","BK0188":"融资融券"},"translate_title":"上海医药（601607.SH）：硫酸羟氯喹片获菲律宾药品注册证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration certificate from the Philippine Food and Drug Administration for its hydroxychloroquine sulfate tablets, approving the drug for market launch.\nHydroxychloroquine sulfate tablets are primarily used to treat rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin conditions triggered or worsened by sunlight.\nThe approval of hydroxychloroquine sulfate tablets (200mg) by the Philippine FDA signifies that the company is now qualified to sell the drug in the Philippine market. This milestone is expected to positively impact Shanghai Pharmaceuticals' overseas expansion efforts while providing valuable experience in international market development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}